MITA, the premier trade association representing manufacturers of medical imaging equipment, radiopharmaceuticals, contrast media, and focused ultrasound therapeutic devices, is pleased that the Food and Drug Administration has approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway, giving hope to those who suffer from Alzheimer’s Disease. We now call on CMS to formally open a reconsideration of the national coverage determination to remove the onerous coverage barriers for Alzheimer’s disease modifying therapies and PET diagnostics to estimate the brain levels of...